Filing summary
Entity and period: The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2019, filed August 1, 2019. This does not match the request metadata naming Crescent BioPharma, Inc.; verify the filing identity before relying on this summary.
Business context
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drugs. It had no approved products or commercial drug sales. Its lead programs included uproleselan for AML, GMI-1359, and rivipansel, which Pfizer licenses and develops.
Financial performance and position
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 | Comparable 2018 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $13.1 million | $24.8 million | $9.3 million / $18.3 million |
| General and administrative expense | $3.8 million | $7.1 million | $2.8 million / $5.7 million |
| Net loss | $15.8 million | $29.9 million | $11.3 million / $22.8 million |
| Net loss per share | $0.37 | $0.69 | $0.26 / $0.58 |
For the six months, operating cash use was $25.7 million, investing cash use was $0.1 million, and financing provided $0.1 million; cash declined by $25.8 million. Cash and equivalents were $184.2 million at June 30, down from $209.9 million at year-end 2018. Accumulated deficit was $230.5 million. The company reported no borrowings; operating lease liabilities totaled $3.9 million, including current and noncurrent amounts. Profit margins are not meaningful because the company had no revenue and incurred operating losses.
Changes versus prior period
- Second-quarter R&D expense rose 40% and first-half R&D rose 36% year over year, primarily due to uproleselan Phase 3 clinical development and increased manufacturing and clinical-trial costs.
- G&A expense increased 32% for the quarter and 25% for the first half, reflecting higher personnel, stock compensation, and legal costs.
- First-half net loss increased $7.1 million year over year. Higher interest income partly offset increased expenses.
- Unlike first-half 2018, which included $128.4 million of net public-offering proceeds, first-half 2019 had no ATM or public-offering proceeds; financing cash flow was mainly option exercises.
Outlook, risks, and notable items
- Management expected cash and equivalents to fund operations at least through preliminary results from the uproleselan Phase 3 trial in relapsed/refractory AML, anticipated by the end of 2020. The estimate depends on assumptions that may prove incorrect; the filing also states funds were expected to cover at least 12 months from filing.
- Top-line results from Pfizer’s rivipansel Phase 3 trial were expected in the third quarter of 2019; Pfizer completed enrollment in May 2019. GlycoMimetics recognized no Pfizer revenue in the first half of 2019.
- The company expected to initiate a Phase 1b GMI-1359 study in breast cancer patients in the second half of 2019. An NCI-supported uproleselan trial in older adults with newly diagnosed AML enrolled its first patient in April 2019.
- Management expected continued losses and negative operating cash flows. Additional capital may be needed, and financing may be unavailable or dilutive. Clinical outcomes, regulatory approval, manufacturing, commercialization, and reimbursement remain significant uncertainties.
- Potential Pfizer milestone payments and royalties are contingent and uncertain. The company reported no material legal proceedings and no material change to the risk factors described in its 2018 Form 10-K.
- Adoption of lease accounting in 2019 added right-of-use assets and lease liabilities; the filing says adoption did not materially affect earnings or cash flows.
Facts investors should verify
- Confirm that GlycoMimetics, rather than Crescent BioPharma, is the intended issuer and filing.
- Check the reported outcomes and timing of the uproleselan and rivipansel trials against subsequent disclosures.
- Assess actual cash burn, trial and manufacturing spending, and whether the stated runway assumptions held.
- Review whether Pfizer milestones or royalties were triggered and the status of the licensing arrangement.